Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.72 USD
Change Today +0.03 / 4.38%
Volume 164.6K
IBIO On Other Exchanges
As of 8:04 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

ibio inc (IBIO) Key Developments

iBio, Inc. Presents at 5th LD Micro Invitational Conference, Jun-01-2015 11:30 AM

iBio, Inc. Presents at 5th LD Micro Invitational Conference, Jun-01-2015 11:30 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Blvd, Los Angeles, CA 90049, United States.

iBio, Inc. Arranges Production of iBio CFB03 for Clinical Development with Caliber Biotherapeutics

iBio Inc. has engaged Caliber Biotherapeutics LLC to scale-up and produce materials for clinical development of the first of iBio's proprietary anti-fibrosis products, IBIO-CFB03. Caliber's production will be used for IND-enabling toxicology studies and initial human clinical trials of IBIO-CFB03. The expansion in 2014 of iBio's exclusive technology collaboration with Novici Biotech LLC broadened iBio's fibrosis therapeutics program through a combination of the strengths of iBio's proprietary iBioLaunch(TM) platform technology with Novici's patented optimization technology. iBio then engaged CBR International Corporation for strategic regulatory and clinical services and assembled a Clinical Advisory Board of internationally recognized experts in fibrotic diseases to assist the company in clinical product development and human trial design.

iBio, Inc. announced delayed 10-Q filing

On 02/17/2015, iBio, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Levi & Korsinsky Announces Class Action Lawsuit iBio, Inc

Levi & Korsinsky announced that a class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased iBio, Inc. securities between October 13, 2014 and October 23, 2014. The complaint alleges that during the class period, the company issued materially false and misleading statements to investors by wrongfully suggesting that the company's launch platform patents and related proprietary technology would be licensed by the makers of the experimental Ebola drug, ZMapp. The complaint alleges that when the true facts were revealed, the price of the company's stock fell significantly, damaging investors.

iBio, Inc., Annual General Meeting, Dec 10, 2014

iBio, Inc., Annual General Meeting, Dec 10, 2014., at 10:00 US Eastern Standard Time. Location: Omni Berkshire Place Hotel, 21 East 52 Street. Agenda: To elect two directors each to serve as Class III directors for a three year term expiring at the 2017 annual meeting of stockholders or until successors have been duly elected and qualified; to ratify the appointment of CohnReznick LLP as the company's independent registered public accounting firm for the fiscal year ending June 30, 2015; to approve an advisory vote on executive compensation; and to transact any other business properly brought before the annual meeting.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IBIO:US $0.72 USD +0.03

IBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IBIO.
View Industry Companies

Industry Analysis


Industry Average

Valuation IBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.7x
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 25.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IBIO INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at